Clinical trial
A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
NCT00422344 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00422344 |
|---|---|
| Title | A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma |
| Official title | A Phase I Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma Patients |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma, Kidney Cancer |
| Intervention type | Drug |
| Interventions | RAD001, Sunitinib |
| Enrollment | 20 |
| Start date | Oct 1, 2006 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Jan 15, 2007 |
| Last update posted | Feb 26, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: